TY  - JOUR
AU  - Saiz, M. L.
AU  - Lozano-Chamizo, L.
AU  - Florez, A. B.
AU  - Marciello, Marzia
AU  - Diaz-Bulnes, P.
AU  - Corte-Iglesias, V.
AU  - Bernet, C. R.
AU  - Rodrigues-Diez, R. R.
AU  - Martin-Martin, C.
AU  - Rodriguez-Santamaria, M.
AU  - Fernandez-Vega, I.
AU  - Rodriguez, R. M.
AU  - Diaz-Corte, C.
AU  - Suarez-Alvarez, B.
AU  - Filice, Marco
AU  - Lopez-Larrea, C.
PY  - 2024
DO  - 10.1016/j.biopha.2024.116492
UR  - https://hdl.handle.net/20.500.14352/137107
T2  - Biomedicine & Pharmacotherapy
AB  - Targeting epigenetic mechanisms has emerged as a potential therapeutic approach for the treatment of kidney diseases. Specifically, inhibiting the bromodomain and extra-terminal (BET) domain proteins using the small molecule inhibitor JQ1 has shown...
LA  - eng
M2  - 116492
PB  - Elsevier
KW  - AKI
KW  - ischemia reperfusion injury
KW  - BRD4 JQ1
KW  - JQ1
KW  - nanobiotechnology
KW  - kidney drug delivery
TI  - BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury
TY  - journal article
ER  -